OBJECTIVES: A potential problem in aortic valve replacement (AVR) for patients with a small aortic annulus is prosthesis-patient mismatch (PPM). Although larger size prostheses have been well studied, the haemodynamics of 19-mm bioprostheses has been reported in only a small number of patients. The Trifecta valve is a novel bioprosthesis and its unique design is conceived to increase effective orifice area (EOA) and prevent PPM. This study aims at comparing the early haemodynamics of the new Trifecta valve with that of other conventional 19-mm valves.
INTRODUCTION
The incidence of calcified aortic valve disease has been increasing in elderly patients and aortic valve replacement (AVR) with a bioprosthesis is the standard therapy for these patients. A potential problem in AVR remains prosthesis-patient mismatch (PPM) as defined by Rahimtoola [1] . It has been proposed that PPM has a significant impact on the short-and long-term outcomes [2] [3] [4] . Therefore, the appropriate prosthesis size must be selected to maximize the effective orifice area (EOA) in order to prevent PPM.
The Carpentier-Edwards Perimount Magna Ease valves (Edwards Lifesciences Corp., Irvine, CA, USA) and the Medtronic Mosaic Ultra valves (Medtronic, Inc., St Paul, MN, USA) have been used in clinical practice with favourable outcomes [5] [6] [7] [8] [9] . Recently, a novel supra-annular aortic valve bioprosthesis, the Trifecta valve (St Jude Medical, Inc., St Paul, MN, USA), was released in Europe, the USA, as well as in Japan. The main innovation includes a design change in which the leaflets are formed as a single pericardial sheet externally mounted on a high-strength titanium stent. In addition, a small sewing ring allows maximal valve haemodynamics. This new bioprosthesis was introduced into clinical practice in April 2012 in Japan. Elderly Japanese patients who require AVR often have a small aortic annulus relative to their body size and usually receive a smaller prosthesis compared with Western patients. However, few studies have directly compared the postoperative haemodynamic performance of the new Trifecta valve with that of conventional bioprostheses in clinical practice, especially among the smallest 19-mm valves [10] [11] [12] [13] . This study aims at comparing the early haemodynamic performance of these supra-annular aortic valve bioprostheses in patients with a small aortic annulus.
MATERIALS AND METHODS
This was a retrospective, single-centre study of 128 consecutive patients who underwent AVR with 19-mm Trifecta, Magna Ease or Mosaic Ultra valves between April 2012 and December 2014 at Saitama International Medical Center. Patients received the Trifecta (n = 39, Trifecta group), Magna Ease (n = 67, Magna group) or Mosaic Ultra (n = 22, Mosaic group) bioprosthesis, depending on the surgeon's criteria. After sizing the annulus with the relevant commercial obturator, a 19-mm bioprosthesis was selected.
Operations were performed using standard cardiopulmonary bypass with mild hypothermia. Myocardial protection was achieved with tepid blood antegrade and retrograde cardioplegia. After aortotomy and excision of the native valve, annular calcification was removed with an aid of Cavitron Ultrasonic Surgical Aspirator to be able to insert as large prosthesis as possible. The prosthesis was sewn in a supra-annular position using non-everting mattress sutures. The surgeon selected which prosthesis would be used, and this selection was not based on clinical or anatomical considerations. The aortotomy was closed using primary sutures. Transoesophageal echocardiography was performed intraoperatively in all patients to assess the correct positioning and normal function of the prosthesis.
All patients underwent two-dimensional and Doppler transthoracic echocardiography by an experienced sonographer preoperatively, 1 month after discharge from the hospital and at 1-year follow-up. The peak pressure gradient (PPG) and mean pressure gradient (MPG) were derived from transaortic flow recorded with continuous-wave Doppler. The preoperative aortic valve area (AVA) and the postoperative EOA were calculated using the continuity equation. The AVA index and the EOA index (EOAI) were calculated as AVA/body surface area (BSA) and as EOA/BSA, respectively. PPM was defined as EOAI <0.85 cm 
Statistical analysis
Descriptive statistics are summarized for categorical variables as frequencies and percentages. Continuous variables are reported as mean ± SD. Groups were compared using Pearson χ 2 tests for categorical variables, one-way analysis of variance (ANOVA) for continuous variables with one independent variable and two-way repeated-measures ANOVA for continuous variables with two independent variables. Analysis of covariance was constructed to compare the primary study endpoints of postoperative MPG, EOAI and left ventricular mass (LV mass). The following postoperative variables were used for the univariate and multivariate analyses: prosthesis type (model of the implanted valve), male sex, age, BSA, body mass index, aortic stenosis, LV ejection fraction (LVEF), New York Heart Association (NYHA) class, hypertension, degenerative calcified, concomitant valve surgery, concomitant coronary artery bypass grafting surgery, European System for Cardiac Operative Risk Evaluation (EuroSCORE), LV mass and LV mass index. Those variables identified by the univariate analysis with P < 0.1 were added to the multivariable model, in addition to the model of implanted prosthesis. In general, P < 0.05 indicated statistical significance. All statistical analyses were performed using JMP, version 10.0 (SAS, Inc., Cary, NC, USA).
RESULTS
Patient baseline characteristics are given in Table 1 . No significant differences were seen in preoperative characteristics between the three different types of bioprostheses. Preoperative echocardiographic data are given in Table 2 . Although mean aortic valvular annulus size in the Mosaic group was smaller than that of the two other groups (Trifecta: 20.6 ± 1.9 vs Magna: 20.7 ± 1.8 vs Mosaic: 19.6 ± 1.9 cm; P = 0.076), no significant differences were observed in preoperative echocardiographic data between the three groups.
Intraoperative data are given in Table 3 . Significant differences were observed in aortic cross-clamp time without a concomitant procedure (Trifecta: 83.2 ± 15.1 vs Magna: 101.1 ± 27.8 vs Mosaic: 108.5 ± 23.0 min; P = 0.002) and cardiopulmonary bypass time without a concomitant procedure (Trifecta: 117.3 ± 29.0 vs Magna: 141.4 ± 37.8 vs Mosaic: 147.0 ± 31.1 min; P = 0.009) between the three groups. All groups had similar rates of concomitant procedures.
There was no difference in postoperative clinical outcomes between the three groups. Postoperative echocardiographic data at 1 month after discharge are presented in Table 4 and Fig. 1 . Among the three groups, the MPG and PPG were the smallest (P < 0.001) and the EOA and EOAI were the largest (P < 0.001) in the Trifecta group, although there was no difference in LVEF between the three groups (Trifecta: 65.2 ± 13.2% vs Magna: 63.1 ± 11.6% vs Mosaic: 65.9 ± 13.7%; P = 0.555). The rate of PPM after implantation of the Trifecta, Magna Ease and Mosaic Ultra valves was 0% (0/39), 60% (40/67) and 59% (13/22) , and the rate of severe PPM was 0% (0/39), 12% (8/67) and 14% (3/22) . In the Trifecta group only, there was no PPM observed (P < 0.001).
To further control for study bias, an analysis of covariance was constructed based on 15 major risk factors, to evaluate possible factors influencing the primary study endpoints of postoperative MPG and EOAI (Table 5 ). In the univariate model, prosthesis type, male sex, EuroSCORE, LV mass and LV mass index were strongly associated with MPG, and prosthesis type, male sex, age, BSA, EuroSCORE, LV mass and LV mass index were strongly associated with EOAI. In the multivariate model, prosthesis type was an independent factor associated with MPG (P < 0.001) and EOAI (P < 0.001).
Echocardiographic data at 1-year follow-up are given in Table 6 and Fig. 1 . Among the three groups, the MPG and PPG were the smallest (P < 0.001) and the EOA and EOAI were the largest (P < 0.001) in the Trifecta group. LV mass regression was significantly observed in the Trifecta and Magna groups and was not observed in the Mosaic group (P = 0.0214).
DISCUSSION
The incidence of calcified aortic valve disease is increasing in elderly patients; AVR with bioprostheses is a standard therapy for these patients because of the advantage of established durability, although transcatheter AVR (TAVR) has been approved for the treatment of high-risk patients with critical aortic stenosis. In Japan, bioprostheses are currently implanted in 73% of patients who require isolated AVR [14] and the rate is still increasing because of the advantage of not requiring anticoagulation therapy, increased durability, ease of implantation and improved haemodynamic performance. However, bioprostheses also have the potential for structural valve deterioration as well as a relatively smaller EOA, compared with mechanical prostheses [4, 15] . A potential problem in AVR using bioprostheses for patients with a small aortic annulus is PPM. Some studies have shown that PPM has an unfavourable impact on the short-and long-term outcomes after AVR [1] [2] [3] [4] . Therefore, especially in cases of a small aortic annulus, surgeons need a prospective strategy that includes selection of the appropriate prosthesis to avoid PPM. However, there is a paucity of literature on the haemodynamic performance of the smallest 19-mm bioprostheses. To our knowledge, this is the first study to compare early haemodynamic performance of the Trifecta valve with that of 19-mm Magna Ease and Mosaic Ultra valves. Moreover, this study represents the largest number of patients treated with the 19-mm Trifecta valve among singlecentre studies.
In cases where severe PPM cannot be avoided with the use of currently available prostheses, aortic root enlargement may be contemplated if the risk-benefit ratio is considered acceptable. Aortic root enlargement is a surgical technique to accommodate a valve with a larger EOA and thereby avoiding PPM, although none of these studies have shown that annulus enlargement results in improved long-term survival [16] . It has been reported that PPM is more common in patients with AVR compared with patients with TAVR [17] . TAVR may thus provide another potential alternative to avoid PPM in high-risk patients and yet provide a less invasive procedure. Although initial results with TAVR are promising, further studies in larger series of patients and long-term outcomes are needed to corroborate the usefulness of this procedure for the prevention of PPM. [9] . In 22 patients undergoing Mosaic ultra implantation in this study, we demonstrated an MPG of 18.6 ± 6.9 mmHg, PPG of 34.9 ± 11.4 mmHg, EOA of 1.15 ± 0.22 cm 2 and EOAI of 0.87 ± 0.22 cm 2 /m 2 in 22 patients with 19-mm Mosaic Ultra valves. In our series with the 19-mm Mosaic Ultra valves, PPM was observed in 13 patients (59%), and severe PPM was found in 3 patients (14%). There remains a paucity of real-world haemodynamic data on the new bioprosthesis Trifecta valve. Bavaria et al. [19] reported an MPG of 9.3 mmHg, PPG of 17.8 mmHg, EOA of 1.58 cm 2 [20] . Although it was reported that bioprostheses have the potential for a relatively smaller EOA compared with mechanical prostheses [15] , the 19-mm Trifecta valves had a similar EOA compared with the St Jude Medical Regent. Bapat et al. measured the true internal diameter, which was defined as the internal diameter of the inflow of various surgical heart valves, with a Hegar dilator. In a porcine surgical heart valve such as the Mosaic valve, the porcine leaflets are always sutured inside the stent frame and, because of their natural hinge point mechanism, tend to encroach maximally inside the stent. Thus, the true internal diameter is reduced by at least 2 mm. The range of reduction could be 2-4 mm and was the largest in larger label sizes. The variability is due to the fact that these leaflets are hand-sewn, and porcine leaflets from different pigs, even when matched, can vary in their thickness. In a pericardial surgical heart valve such as the Magna valve, the thickness of the bovine pericardium for the leaflets is controlled and matched, and the way the pericardium is sutured inside the stent leads to a reduction in the stent internal diameter by only 1 mm. In terms of design such as that of the Trifecta valve, because the sheet of pericardium is wrapped outside the stent, the leaflets have no effect on the stent internal diameter. Thus, the unique design of the Trifecta valve enables one to increase EOA and prevent PPM [21] . Echocardiographic data at 1-year follow-up demonstrated an MPG of 12.8 ± 3.6 mmHg, PPG of 23.8 ± 7.1 mmHg, EOA of 1.50 ± 0.30 cm 2 and EOAI of 1.07 ± 0.23 cm 2 /m 2 . The MPG and PPG at 1-year follow-up were a little higher than those at 1 month after discharge, and the EOA and EOAI were a little lower than those at 1 month after discharge, although the haemodynamic performance was best in the Trifecta group among the three groups. Banbury et al. [22] reported that in the Carpentier-Edwards aortic pericardial valve bioprosthesis, increases in the MPG are seen early in the life of the valve, and later changes are limited, and the EOA shows an early decrease and then an increase in magnitude such that at 17 years, it is similar to that found at 3 years. Ruggieri et al. [23] reported that mean MPG showed a non-significant increase at 1-year follow-up with respect to discharge echocardiography, followed by a secondary decrease at the 3-year time point. The new 19-mm Trifecta valve had favourable early haemodynamic performance compared with that of the conventional valves, and it may be useful for preventing PPM in patients with a small aortic annulus. However, further evaluations in a larger number of patients during long-term follow-up are needed to confirm the promising results of this innovative bioprosthesis.
LV mass regression after AVR is considered a result of favourable remodelling. LV mass has been used to assess the adequacy of AVR and has been shown to be a significant prognosis indicator for long-term outcome. Some studies have shown a significant regression of LV mass in favour of patients without PPM [2, 24] . In the present study, postoperative echocardiography at 1 month after discharge showed a decrease in the LV mass from the preoperative value, regardless of the prosthesis type and PPM. However, echocardiographic data at 1-year follow-up showed LV mass regression in the Trifecta group and the Magna group, not in the Mosaic group. Oppell et al. [25] reported that although severe PPM was identified in a higher proportion of Ultra patients than Magna patients, both groups showed a similar level of LV mass regression. In the Mosaic group, although there were no changes in the EOA and EF during 1-year follow-up period, the MPG and PPG at 1-year follow-up were significantly higher than those at 1 month after discharge. It might relate the poor remodelling in patients who underwent AVR with the Mosaic valve. Our study demonstrated the favourable remodelling in patients who underwent AVR with the Trifecta valve, which had the lowest rate of PPM.
Limitations
The study design was retrospective and was not randomized. Therefore, preoperative characteristics, operative procedure and conditions were not identical between the three valve groups.
Among single-centre reports, the present study represents the largest number of patients treated with the 19-mm Trifecta valve. Although the P-value was not significant (0.076), the preoperative mean aortic valvular annulus size in the Mosaic group was smaller than the two other groups and it influenced the poorer haemodynamic outcomes in that group. Because of the different valve designs, the three prostheses used in this study might have different inner diameters even among the same-sized valves [9] ; thus, this study might be biased by an unequal size distribution. Although the early haemodynamic performance at 1 month after discharge is excellent, the durability is also an important factor of bioprostheses. To evaluate the durability, further studies of longterm outcomes focused on structural valve deterioration and on valve-related complications are needed.
CONCLUSION
The new Trifecta valve had favourable early haemodynamic performance in patients with a small aortic annulus compared with patients with the conventional 19-mm Magna Ease valve and the Mosaic Ultra valve. The 19-mm Trifecta valve may be useful for preventing PPM in patients with a small aortic annulus, and such a valve is necessary in the TAVR era. Further evaluations in a larger number of patients during long-term follow-up are needed to confirm the promising results of this innovative bioprosthesis.
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